Johnson & Johnson to Acquire Halda Therapeutics OpCo for $3.05 Billion

Cravath, Swaine & Moore LLP represented client Johnson & Johnson in connection with the transaction. On November 17, 2025, Johnson & Johnson announced that it had entered into a definitive agreement to acquire Halda Therapeutics OpCo, Inc. for $3.05 billion in cash. Halda is a clinical‑stage biotechnology company that employs a proprietary Regulated Induced Proximity TArgeting Chimera (RIPTACTM) platform to develop oral, targeted therapies for multiple types of solid tumors, including prostate cancer. Cravath, Swaine & Moore LLP represented client Johnson & Johnson with a team composed by: partners Robert I. Townsend III and Jin‑Kyu Baek and associates Josh Santilli, Evan S. Gabor and Y. Amy Chun on M&A matters; partners J. Leonard Teti II and Andrew T. Davis and associates Carlos Nicholas Obando and Ruth Goldstein Schapiro on tax matters; partner Matthew J. Bobby, of counsel Sarah W. Colangelo and associate Caroline Wyatt on executive compensation and benefits matters; partner Sasha Rosenthal‑Larrea, of counsel Kathryn‑Ann Stamm and associates M. Noa Ma and Liza C. Clark on intellectual property matters; partner Matthew Morreale on environmental matters; and senior attorney Joyce Law and practice area attorney Brian M. Budnick on real estate matters. Leon K. Yang and Alexandra E. Stolfe also worked on M&A matters and Nilofar Vakili also worked on intellectual property matters.

Johnson & Johnson to Acquire Halda Therapeutics OpCo for $3.05 Billion

Read the full story

Cookie Preferences

Strictly Necessary

Analytics & Statistics

Marketing & Ads